KMT2A FISH
Also known as: MLL (mixed-lineage leukaemia) FISH
Test category:
Oncology - Leukaemia
Use of test
Purpose:
MLL (also known as KMT2A) is located at 11q23. It can undergo gene fusion with a variety of partner genes in several types of acute leukaemia. This fusion carriers prognostic implications.
Utility:
Presence of an MLL fusion gene is typically associated with a poor prognosis.
Ethical considerations:
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Methodology:
Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of MLL with various partner genes.
Requesting the test
Ordering:
This test is usually requested by a haematologist or oncologist.
Sample required:
0.5 mL bone marrow in transport media, or 10 mL blood in lithium heparin.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
Turnaround time:
2 business days.
Price:
This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.
Rebate:
The Medicare details, including descriptor and schedule fee, are listed under MBS item 73314.